Orthocell acquires IP and a new chairman
12 May, 2014Regenerative medicine company Orthocell has acquired key pieces of intellectual property (IP) from its research partners at The University of Western Australia (UWA). The company has also welcomed the appointment of Dr Stewart Washer to its board as chairman.
Qiagen products cleared by FDA
08 May, 2014The US FDA has cleared the Qiagen artus C. difficile QS-RGQ MDx Kit to qualitatively detect Clostridium difficile, a widespread healthcare-associated infection. The test was developed in partnership with IntelligentMDx and CE marked in December 2013.
New CSIRO lab and board member
08 May, 2014CSIRO and Deakin University have officially opened the new Biosecure Immunology Laboratory. CSIRO has also announced the appointment of biotechnologist Dr Peter Riddles as a part-time member of the organisation's board.
First international guests announced for NZ Scifest
05 May, 2014This year's New Zealand International Science Festival (Scifest) will be held in Dunedin from 5-13 July. The aim of the event is to promote and celebrate science, technology and the natural environment to a wide general audience, showing that science is exciting, fun and accessible.
Lonza certification and committee changes
29 April, 2014Lonza Bioscience Singapore has received cGMP certification from the Singapore Health Sciences Authority (HSA) for its cell-therapy manufacturing facility, while Lonza Group has announced changes in the composition of its executive committee (EC).
Honey researcher receives USC Chancellor's Medal
29 April, 2014Environmental scientist Daniel Meloncelli has been awarded a University of the Sunshine Coast (USC) Chancellor's Medal. It was one of only three Chancellor's Medals presented at USC's recent graduation ceremonies, awarded to outstanding graduates who have contributed to the university or wider community and achieved a high academic level during their studies.
US excipients market forecast to rise
28 April, 2014US research firm The Freedonia Group has released the report 'Excipients', an industry study showcasing trends and forecasts in the pharmaceutical excipients market. The study also analyses market environment factors, evaluates company market share and profiles 47 US industry competitors.
Coastal research centre for China and New Zealand
23 April, 2014The University of Waikato has signed an agreement with the Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, to establish a coastal biotechnology research centre. With bases in both Tauranga and China, the China-New Zealand Coastal Biotechnology Joint Research Centre would aim to integrate China and New Zealand's coastal biotechnology research experts.
CSIRO bracing for cuts, claims Fairfax
16 April, 2014 by Lauren DavisFairfax Media has published an article claiming that science body CSIRO is bracing for a May budget cut of up to $150 million, or more than 20% of its total government funding, with the organisation's top executive team modelling a range of scenarios based around this outcome.
Merck Millipore announces incoming CEO and president
15 April, 2014Merck Millipore, the life science division of Merck, has announced the appointment of Dr Udit Batra as its incoming president and CEO. Dr Batra comes to Merck Millipore from the consumer health division of Merck KGaA, where he successfully grew the business in established and emerging markets.
Renowned biological scientist elected to Australian Academy of Science
14 April, 2014A leading British scientist, Professor Sir Philip Cohen FAA FRS FRSE, has been announced as a Corresponding Member of the Australian Academy of Science.
Qiagen acquires biomarker for blood disorders
14 April, 2014Qiagen has acquired an exclusive worldwide licence to the biomarker calreticulin (CALR), whose mutations are found in an estimated 15% of cases of myeloproliferative neoplasms (MPNs) - a group of blood disorders involving overproduction of blood cells.
Olympus opens new operational headquarters
11 April, 2014Olympus Australia has moved its operational headquarters to a state-of-the-art facility in Melbourne that incorporates a fully operational customer experience centre, comprehensive training facilities and the company's national service centre.
$48 million funding boost for chronic pain treatment
11 April, 2014Australian biotech company Spinifex Pharmaceuticals has attracted $48 million in funding to advance its drug for chronic pain, EMA401. The deal represents one of Australia's largest off-market investments in a private biotechnology company.
E-commerce in the lab
09 April, 2014 by Karl Wyzenbeek, Managing Director, LabFriend | Supplied by: LabFriendConsumers in Australia have adopted the web as the go-to resource to find the best price on products from around the world. But while we shop online for ourselves looking for a bargain, are we doing this in the laboratory?
